Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1894-2026

LeadCare Plus Blood Lead Test Kit; Recall

LeadCare¿ Plus Blood Lead Test Kit; Catalog Number: 82-0004; The LeadCare¿ Plus kit is provided with the following materials: " Sensors (4 containers of 24 each; 96 tests) " Treatment Reagent Tubes (4 packages of 24 each; 96 tests) " Calibration Button (1 @) " Lead Control Level 1 (1 @ 2 mL) " Lead Control Level 2 (1 @ 2 mL)

FDA recall Class II

Ongoing

FDA lists this Class II recall for LeadCare Plus Blood Lead Test Kit;. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1894-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Mar 13, 2026
FDA report date
Apr 29, 2026
Quantity in commerce
136
Distribution
See key details
FDA cause
Device Design

What is being recalled?

LeadCare Plus Blood Lead Test Kit; Catalog Number: 82-0004; The LeadCare Plus kit is provided with the following materials: " Sensors (4 containers of 24 each; 96 tests) " Treatment Reagent Tubes (4 packages of 24 each; 96 tests) " Calibration Button (1 @) " Lead Control Level 1 (1 @ 2 mL) " Lead Control Level 2 (1 @ 2 mL)

Affected model & UDI checker

Search the exact identifiers published for Z-1894-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
82-0004LeadCare Plus Blood Lead Test Kit;Check source noticeNot specified
Not specifiedLeadCare Plus Blood Lead Test Kit;Check source notice00850355006031
FDA code information

Catalog Number: 82-0004; UDI-DI: 00850355006031; ALL lots and ALL sublots;

View the original FDA recall notice

Why was this product recalled?

Customers reported observing unexpectedly elevated results when using certain third-party micro-collection devices to collect capillary samples for testing with the LeadCare Test Systems. False positive lead results may cause delayed results and additional unnecessary testing.

What actions did Magellan Diagnostics, Inc. take?

On March 13, 2026, MEDICAL DEVICE FIELD CORRECTION letters were sent to customers. REQUIRED ACTIONS: This field action does NOT require removal of product from the field. The LeadCare Test Systems continue to perform as intended when used according to the product labeling and Instructions for Use. The regulatory status of all products noted above remains unchanged and the product supply uninterrupted. Technical and customer support will continue as normal. LEADCARE II: The only blood collection devices validated for use with the Magellan LeadCare II Blood Lead Test Kit are the capillary tubes provided in the LeadCare II Test Kit. No other collection device should be used for blood sample collection for testing with the LeadCare II System. LEADCARE PLUS AND ULTRA: End users must validate the use of micro-collection devices with LeadCare Plus and LeadCare Ultra Blood Lead Testing Systems in accordance with their laboratory policies and procedures. REGARDING PREVIOUS RESULTS: Patients who have had elevated results when tested on the LeadCare Blood Lead Test Systems (LeadCare II, LeadCare Plus, and LeadCare Ultra) should have confirmatory testing performed in accordance with CDC or other applicable standards and guidelines.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology